Deep Sequencing to Identify B-Cell Precursors of HIV-1 Neutralizing Antibodies
深度测序鉴定 HIV-1 中和抗体的 B 细胞前体
基本信息
- 批准号:9285702
- 负责人:
- 金额:$ 48.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-07-01 至 2019-06-30
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAffinityAntibodiesAntibody RepertoireAntibody ResponseAntigensAutologousB-LymphocytesBindingBloodBlood CellsBlood specimenCellsCloningComplexCritical PathwaysDevelopmentEpitopesGenomeGlycoproteinsGoalsHIV-1HumanImmunityImmunizationImmunologicsIndividualInfectionMacaca mulattaMonoclonal AntibodiesPlasmaProcessProductionReceptors, Antigen, B-CellResolutionSamplingSystemTechnologyTestingTimeVaccinationVaccine DesignVirusantigen bindingdeep sequencingdesignimmunogenicityinsightinterestlymph nodesneutralizing antibodyneutralizing monoclonal antibodiespublic health relevanceresponsescreeningsimian human immunodeficiency virusvaccine development
项目摘要
DESCRIPTION: Our recent breakthroughs in applying single B-cell probing and cloning technologies to isolate human antibodies capable of potently and broadly neutralizing HIV-1 primary isolates, along with others, have demonstrated the ability of human B-cell system to generate effective immunity against the virus. To progress on this encouraging discovery and unearth mechanisms by which broadly neutralizing antibodies (bnAbs) could be elicited by immunization, we are challenged by two unsolved and fundamental immunological questions: what are the naive and/or founder (n/f) B-cells and their B-cell receptor (BCR) sequences that must be immunologically selected to generate anti-HIV-1 bnAbs, and how do these selected n/f BCRs react with the HIV-1 envelope (Env) antigen? Having access to precious longitudinal samples from both SHIV-infected rhesus macaques (including lymph nodes) and HIV-1- infected seroconverters, we have a unique opportunity to address these questions by identifying the n/f BCRs responsible for bnAbs and determining their reactivity to the Env antigen. In addition to single B-cell analysis, we have also pioneered the application of deep sequencing technology to mine anti-HIV-1 bnAbs of the whole antibody repertoire. With the aid of these advanced technologies that offer high- resolution analysis of both single and high-number (millions) B-cells, it is feasible to track bnAb responses, thereby catapulting our quest to identiy bnAb-corresponding n/f BCRs. Furthermore, we will isolate the autologous infecting HIV-1 Envs and investigate their reactivity with the n/f BCRs of interest. We will test the hypotheses that n/ BCRs that give rise to bnAbs in SHIV-infected rhesus macaques and HIV-1-infected humans can be identified by deep sequencing of the subject antibodyome from longitudinally collected blood and lymph node cells, and that the n/f BCRs recognize the autologous infecting HIV-1 Envs. If successful, this project will delineate a complex and lengthy B-cell immunological process, revealing the much anticipated initial steps that the HIV-1 Env antigen must take to initiate an effective antibody response. This project will also generate a panel of bnAb-corresponding n/f BCRs that would be invaluable for immunogen screening and may also identify HIV-1 Envs that have the potential to prime these n/f BCRs.
产品说明:我们最近在应用单B细胞探测和克隆技术分离能够有效和广泛中和HIV-1主要分离物的人抗体方面取得的突破,沿着其他人,已经证明了人B细胞系统产生针对病毒的有效免疫力的能力。为了在这一令人鼓舞的发现上取得进展,并发掘通过免疫可以引起广泛中和抗体(bnAb)的机制,我们面临着两个未解决的基本免疫学问题的挑战:必须通过免疫学选择以产生抗HIV-1 bnAb的初始和/或建立者(n/f)B细胞及其B细胞受体(BCR)序列是什么,这些选择的n/f BCR如何与HIV-1包膜(Env)抗原反应?在获得来自SHIV感染的恒河猴(包括淋巴结)和HIV-1感染的血清转换者的珍贵纵向样本后,我们有一个独特的机会通过鉴定负责bnAb的n/f BCR并确定其对Env抗原的反应性来解决这些问题。除了单个B细胞分析,我们还率先应用深度测序技术挖掘整个抗体库的抗HIV-1 bnAb。借助于这些提供单个和大量(数百万)B细胞的高分辨率分析的先进技术,追踪bnAb应答是可行的,从而促进了我们对鉴定bnAb对应的n/f BCR的探索。此外,我们将分离自体感染的HIV-1 Env,并研究其与目标n/f BCR的反应性。我们将检验以下假设:在SHIV感染的恒河猴和HIV-1感染的人中产生bnAb的n/BCR可以通过对纵向采集的血液和淋巴结细胞中的受试者抗体组进行深度测序来鉴定,并且n/f BCR识别自体感染的HIV-1 Env。如果成功,该项目将描绘一个复杂而漫长的B细胞免疫过程,揭示HIV-1 Env抗原启动有效抗体反应所必须采取的备受期待的初始步骤。该项目还将产生一组bnAb对应的n/f BCR,这对免疫原筛查非常宝贵,也可能鉴定出有可能引发这些n/f BCR的HIV-1 Env。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Xueling Wu其他文献
Xueling Wu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Xueling Wu', 18)}}的其他基金
Characterization of HIV-1 IgA bNAbs and ADCP function
HIV-1 IgA bNAb 的表征和 ADCP 功能
- 批准号:
10686968 - 财政年份:2022
- 资助金额:
$ 48.7万 - 项目类别:
Characterization of HIV-1 IgA bNAbs and ADCP function
HIV-1 IgA bNAb 的表征和 ADCP 功能
- 批准号:
10548376 - 财政年份:2022
- 资助金额:
$ 48.7万 - 项目类别:
Characterization of HIV-1 IgA bNAbs and ADCP function
HIV-1 IgA bNAb 的表征和 ADCP 功能
- 批准号:
10529017 - 财政年份:2021
- 资助金额:
$ 48.7万 - 项目类别:
Novel HIV-1 Env trimer probes for efficient isolation of broadly neutralizing antibodies
用于有效分离广泛中和抗体的新型 HIV-1 Env 三聚体探针
- 批准号:
9335273 - 财政年份:2016
- 资助金额:
$ 48.7万 - 项目类别:
Novel HIV-1 Env trimer probes for efficient isolation of broadly neutralizing antibodies
用于有效分离广泛中和抗体的新型 HIV-1 Env 三聚体探针
- 批准号:
10080301 - 财政年份:2016
- 资助金额:
$ 48.7万 - 项目类别:
Deep Sequencing to Identify B-Cell Precursors of HIV-1 Neutralizing Antibodies
深度测序鉴定 HIV-1 中和抗体的 B 细胞前体
- 批准号:
8789709 - 财政年份:2014
- 资助金额:
$ 48.7万 - 项目类别:
Deep Sequencing to Identify B-Cell Precursors of HIV-1 Neutralizing Antibodies
深度测序鉴定 HIV-1 中和抗体的 B 细胞前体
- 批准号:
8865551 - 财政年份:2014
- 资助金额:
$ 48.7万 - 项目类别:
Deep Sequencing to Identify B-Cell Precursors of HIV-1 Neutralizing Antibodies
深度测序鉴定 HIV-1 中和抗体的 B 细胞前体
- 批准号:
9086242 - 财政年份:2014
- 资助金额:
$ 48.7万 - 项目类别:
Characterization and Generalization of a Novel Immunogenic Target on HIV-1 gp120
HIV-1 gp120 新型免疫原性靶点的表征和推广
- 批准号:
8812773 - 财政年份:2014
- 资助金额:
$ 48.7万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 48.7万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 48.7万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 48.7万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 48.7万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 48.7万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 48.7万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 48.7万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 48.7万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 48.7万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 48.7万 - 项目类别:
Research Grant